Feed CODX
CO

Co-Diagnostics, Inc.

CODX · NASDAQ

$1.01 +2.03% (+$0.02)
1M -17.21%
Market Cap $1.13M
P/E Ratio -
Div. Yield -
ROE 210.99%

Bulios Fair Price

$1.24

22.8% upside

Current Price

$1.01

Undervalued Fair Value Overvalued

According to Bulios Fair Price, CODX is currently undervalued relative to its market price. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Weak
2/9
Valuation
94 /100
Cheap
P/B 0.09x
P/S 1.56x
PEG N/A
Growth
0 /100
Declining
Book val. growth 43.52%
Rev. growth 73.70%
FCF growth N/A
Profitability
0 /100
Weak
FCF margin 3,808.02%
Op. margin 4,170.14%
Gross margin 8.07%
Quality
1 /100
Poor
Asset turnover 0.04x
ROA 283.63%
ROIC 200.40%
Debt
97 /100
Low
Current ratio 1.81x
Debt/Equity 0.14x
Net debt/EBITDA N/A
Stability
15 /100
Unstable
Profitable years 0
EPS volatility 96.08%
Beta 2.86x

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about CODX
Online

About the company

Co-Diagnostics, Inc. (CODX) is an American biotechnology company specializing in the development and manufacturing of diagnostic tests and reagent kits for the detection of various infectious diseases. The company focuses on innovative molecular diagnostic technologies that enable rapid and accurate determination of pathogens in patient samples. Its diagnostic tools are applied in the detection of viral, bacterial, and parasitic infections, serving both as diagnostic and monitoring solutions for diseases. With its advanced diagnostic technologies, Co-Diagnostics can contribute to improving healthcare and reducing the spread of infectious diseases. The company continually emphasizes research and development of new diagnostic tests to meet the needs of the medical community. Co-Diagnostics, Inc. (CODX) shares may be an attractive investment opportunity for investors interested in the healthcare sector and seeking an investment in a company dedicated to innovative diagnostic technologies.

Sector

Healthcare

Industry

Biotechnology

CEO

Dwight Egan

Employees

115

Headquarters

Salt Lake City

Upcoming events

16 NOV

Earnings

Upcoming earnings report

55d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.